To address this gap, we performed a systematic pan-cancer analysis that interrogated DDR1’s diagnostic and prognostic value, genetic alterations, pathway associations, and immunotherapeutic relevance across multiple tumor types. The gene discussed is DDR1; the disease is cancer.